DRCT

DRCT is a distressed micro-cap in structural decline. Revenue has cratered from a $157M peak in FY2023 to $62.3M in FY2024 and just $34.7M in FY2025 (-44.3% YoY) — a two-year collapse of roughly 78%. The bottom line moved the wrong way in tandem: FY2025 net income of -$18.9M (down 203.8% YoY) on a -54.6% net margin, with operating income of -$14.8M. Gross margin has compressed to 30.0%, and operating cash flow was -$8.91M, meaning the business burns cash it does not have.

The balance sheet is the disqualifier. Stockholders' equity is negative at -$7.02M (liabilities/equity of -3.87x), retained earnings are -$27.7M, and cash is down to $728K against $12.0M of current debt (up 224.4% YoY) and current liabilities of $26.4M versus only $4.74M of current assets — a working-capital hole of over $21M. The 10-K states this plainly: management discloses 'substantial doubt about our ability to continue as a going concern,' credit-facility covenants that 'impose risk of default,' and explicit risk that the Class A stock 'may be delisted from the Nasdaq Capital Market.' The -$75.79 diluted EPS alongside a $2.85 share price and a 352.9% jump in weighted shares points to a reverse split and heavy dilution — classic signs of a company recapitalizing to survive rather than grow.